We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

92 hedge funds and large institutions have $167M invested in Corvus Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 10

45% more capital invested

Capital invested by funds: $115M → $167M (+$51.7M)

14% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 29

8.03% more ownership

Funds ownership: 53.26% → 61.29% (+8%)

5% more funds holding

Funds holding: 88 → 92 (+4)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

30% less call options, than puts

Call options by funds: $702K | Put options by funds: $1.01M

Holders
92
Holders Change
+4
Holders Change %
+4.55%
% of All Funds
1.21%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
33
Increased
32
Reduced
10
Closed
29
Calls
$702K
Puts
$1.01M
Net Calls
-$308K
Net Calls Change
-$3.1M

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$15.5M
2
BlackRock
BlackRock
New York
+$11.6M
3
PA
Perceptive Advisors
New York
+$5.23M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.86M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.81M

Top Sellers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
-$12.9M
2
Millennium Management
Millennium Management
New York
-$5.96M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$3.21M
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$1.47M
5
Jane Street
Jane Street
New York
-$901K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
76
BNP Paribas Financial Markets
France
$22.2K +$16.8K +4,608 +494%
AIP
77
Ameritas Investment Partners
Nebraska
$21.4K +$19.5K +5,348 New
TC
78
Truvestments Capital
Florida
$19.1K +$17.4K +4,775 New
TRCT
79
Tower Research Capital (TRC)
New York
$16.9K +$4.46K +1,227 +41%
NCM
80
Northwest Capital Management
Oregon
$13.6K – – –
California State Teachers Retirement System (CalSTRS)
81
California State Teachers Retirement System (CalSTRS)
California
$13.1K +$11.9K +3,268 New
Mirae Asset Global Investments
82
Mirae Asset Global Investments
South Korea
$11.9K +$3.39K +931 +45%
CIAM
83
Caitong International Asset Management
Hong Kong
$8.13K +$6.35K +1,745 +608%
WPWM
84
Western Pacific Wealth Management
Illinois
$8K – – –
FIA
85
FNY Investment Advisers
New York
$8K +$7.29K +2,005 New
AB
86
Amalgamated Bank
New York
$7K +$6.51K +1,789 New
GFM
87
GF Fund Management
China
$6.38K – – –
SS
88
SBI Securities
Japan
$4K – – –
Daiwa Securities Group
89
Daiwa Securities Group
Japan
$2K – – –
Comerica Bank
90
Comerica Bank
Texas
$1.46K +$1.33K +365 New
Fidelity Investments
91
Fidelity Investments
Massachusetts
$937 +$833 +229 +4,580%
SCM
92
Sterling Capital Management
North Carolina
$508 +$462 +127 New
SC
93
Samlyn Capital
New York
– -$12.9M -4,065,935 Closed
Millennium Management
94
Millennium Management
New York
– -$5.96M -1,637,138 Closed
ECM
95
ExodusPoint Capital Management
New York
– -$634K -199,358 Closed
American Century Companies
96
American Century Companies
Missouri
– -$284K -89,265 Closed
OAC
97
OMERS Administration Corp
Ontario, Canada
– -$262K -82,300 Closed
HF
98
HRT Financial
New York
– -$260K -81,927 Closed
GCM
99
Graham Capital Management
Connecticut
– -$215K -67,550 Closed
Citadel Advisors
100
Citadel Advisors
Florida
– -$224K -61,676 Closed
1 2 3
4
5

CRVS Hedge Fund Activity: Q2 2025 in Review

92 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2025, worth a combined $167M — up 45% from $115M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new CRVS positions and 29 closed out — a net gain of 4 holders — while 32 added to existing stakes and 10 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $15.5M. The largest seller was Samlyn Capital, exiting entirely with an estimated $12.9M sold.

  • 92 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2025, up from 88 in Q1 2025.
  • Funds reported $167M of Corvus Pharmaceuticals stock for Q2 2025, up 45% quarter-over-quarter.
  • 33 funds opened new Corvus Pharmaceuticals positions in Q2 2025 and 29 closed out, a net change of +4 holders.
  • The largest Corvus Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $15.5M added.
  • The largest Corvus Pharmaceuticals seller in Q2 2025 was Samlyn Capital, an estimated $12.9M sold.

Based on aggregated 13F filings for Q2 2025.